Cite
HARVARD Citation
Henderson, R. et al. (2021). Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine. 100 (42), pp. e27421-. [Online].